Etofenamat
PreclinicalSmall molecule
Etofenamat is one of 12 small molecule programs targeting Sprain. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Sprain
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Zyloprim
Jazz PharmaceuticalsApproved
Keflex
Eli LillyApproved
Oruvail
WWyeth-Lederle Vaccines
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Indocin
CCosette Pharmaceuticals, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sprain1 trial
Topical Treatments for Ankle Sprains
Active, not recruiting·—··NCT06623929·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Etofenamat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAnkara City Hospital Bilkent